Cognitive Exercise Therapy Approach (BETY) in Parkinson's Disease

March 18, 2025 updated by: Orkun Tüfekçi

Investigation of the Effectiveness of Cognitive Exercise Therapy Approach (BETY) in Parkinson's Disease

Considering the impact of motor and non-motor findings on movement problems in the disease management of people living with PD, biopsychosocial evaluation and treatment approaches are essential. However, there are not many studies investigating the impact of a biopsychosocial-based exercise approach on the biopsychosocial characteristics of individuals in PD management.

The Cognitive Exercise Therapy Approach (BETY), an innovative exercise approach based on the biopsychosocial model, has been developed with the participation of individuals with rheumatism in exercise sessions for many years. This study investigated the effects of the BETY, a supervised biopsychosocial model-based exercise intervention, on cognitive status, physical activity, balance, and biopsychosocial status in people living with PD.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alanya
      • Antalya, Alanya, Turkey, 07425
        • Alaaddin Keykubat University
    • Altındağ
      • Ankara, Altındağ, Turkey, 06100
        • Hacettepe University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosed with idiopathic Parkinson's disease
  • between 1-3 at home according to Modified Hoehn and Yahr Staging (MH&Y)

Exclusion Criteria:

  • Individuals who were diagnosed with dementia before Parkinson's diagnosis
  • Had undergone deep brain stimulation
  • Diagnosed with psychiatric or additional neurological diseases
  • Had limited physical activity due to orthopedic problems or previous neurological diseases
  • Had communication problems

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: BETY session group
Parkinson's Disease participating in BETY sessions.
The cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) will be applied for 24 one-hour sessions, two days a week.
No Intervention: Control Group
Control groups continued their disease management under the follow-up of their neurologists.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
BETY-Biopsychosocial Questionnaire
Time Frame: Three months
Each question of the BETY-BQ consists of 30 items scored between 0-120 as '0 (never), 1 (yes rarely), 2 (yes sometimes), 3 (yes often), 4 (yes always)'. A high score indicates poor biopsychosocial status.
Three months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Beck Depression Scale (BECK-D)
Time Frame: Three months
It assesses the depression status of individuals. It consists of a total of 21 items assessing unhappiness, self-blame, self-dislike, thoughts of failure, irritability, crying, social withdrawal, indecision, fatigue, insomnia, loss of appetite, somatic distractions, and decreased libido. 1-10: Normal, 11-16: Mild mood changes, 17-20: Borderline clinical depression, 21-30: Moderate depression, 31-40: Severe depression, 40: Very severe depression
Three months
International physical activity questionnaire-Short (IPAQ-Short)
Time Frame: Three months
The scale includes questions about physical activity lasting at least 10 minutes or more in the last 1 week. The IPAQ-Short uses the Metabolic Equivalent (MET) method for physical activity level. Fixed MET values were determined for each section of the scale. These MET values are: Vigorous physical activity, 8 METs; moderate physical activity, 4 METs; walking, 3.3 METs; sitting, 1.5 METs. These MET values are multiplied by the time spent and the number of days, and the results for each activity are summed, and the total MET value is found. Total score values are in MET-minutes/week: Low-level physical activity - Total score < 600 MET min/week, Moderate physical activity - 3000 MET min/week > Total score ≥ 600 MET min/week, High-level physical activity - Total score ≥ 3000 MET min/week.
Three months
Berg Balance Scale (BBS)
Time Frame: Three months
The Berg Balance Scale (BBS) assesses the risk of falling in 14 situations that individuals may encounter daily. Each item is scored between 0-4 in this test according to the individual's ability. While a score of 4 indicates that the individual can complete that item, the highest score can be 56 points.0-20: High fall risk, 21-40: Moderate fall risk, 41-56: Low risk
Three months
8-Item Parkinson's Disease Questionnaire (PDQ-8)
Time Frame: Three months
The 8-item Parkinson's Disease Questionnaire (PDQ-8) consists of one item from each of the eight domains of the PDQ-39 (mobility, activities of daily living, emotional well-being, stigma, communication, social support, cognition, and physical discomfort) with the highest item-total correlation. Each question is scored between 0-4, with a total score in the range of 0-32. A higher score indicates a worse quality of life.
Three months
Unified Parkinson's Disease Rating Scale (UPDRS)
Time Frame: Three months
The scale consists of four parts: 1. Mental, behavioral, and mental status (4 questions), 2. Activities of daily living (13 questions), 3. Motor performance (14 questions), 4. Treatment complications (11 questions). It is used to assess motor impairment and disability in Parkinson's disease. The total score of the scale indicates the severity of the disease. A higher score indicates more severe Parkinson's disease.
Three months
Montreal Cognitive Assesment: MoCA
Time Frame: Three months
The Montreal Cognitive Assessment Test (MoCA) is an assessment tool developed to evaluate mild cognitive impairment. MoCA has items that test executive tasks such as abstract thinking, tracing tests, cube copying, clock drawing, similarity, naming, memory and attention, sentence repetition, verbal fluency, delayed recall, and orientation. This test is scored between 0-30. Cognitive status is considered normal above a total score of 21.
Three months
Modified Hoehn & Yahr Staging Scale (MH&Y)
Time Frame: Three months
It is used to determine the degree of disease and symptoms of Parkinson's disease. The scale has a seven-item staging system.
Three months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 7, 2022

Primary Completion (Actual)

August 7, 2023

Study Completion (Actual)

August 31, 2023

Study Registration Dates

First Submitted

March 18, 2025

First Submitted That Met QC Criteria

March 18, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 18, 2025

Last Verified

September 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Will not be shared to protect the data of individuals

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on BETY

Subscribe